Business EconomyPosted at: Apr 25 2025 1:16AM


Laurus labs Q4FY25 net profit rises 208 pc to Rs 234 cr

Hyderabad, Apr 24 (UNI) Laurus Labs Ltd., a leading research and development driven pharmaceutical and biotech company in India, on Thursday said that its net profit increased 208 per cent to Rs 234 crore for the fourth quarter ended March 31,2025 as against Rs 76 crore for the corresponding quarter of FY24.
The Hyderabad-based Pharma Company’s revenues during the quarter rose 19 per cent to Rs 1,720 crore as compared with Rs 1,440 crore in 4QFY24, a release said here.
For the full year, the company’s profit rose 122 per cent to Rs 358 crore as against Rs 161 crore in FY24, while revenues increased to Rs 5,554 crores in FY25 from Rs 5,041 crore in FY24.

Dr. Satyanarayana Chava, Founder & Chief Executive Officer commented; “We delivered very good Q4 results and continued our transformative progress, reflecting robust demand for our CDMO offerings and meeting complex customer needs, supported by growth in FDF division. These results demonstrate the strength of our business model and give us confidence in our outlook. We are deepening our cooperation with major clients, and augmenting it with promising BD and capacity creation. Our business remains well positioned to evolve into a well-diversified CMO/CDMO company with promising pipeline, enabling several technology platforms and commercial excellence, thanks to team commitment to the unified vision of delivering high quality integrated solution and securing our long-term growth potential.”
VV Ravi Kumar, Executive Director & Chief Financial Officer commented; “Despite the ongoing macroeconomic challenges, we have witnessed a high level of demand for our offerings. For Q4, we delivered Rs 1,720 crore in revenues, growth of 19 per cent and Rs 477 crore EBITDA grew by 84 percent, resulting in 27.7 percent margin. Gross margins remained healthy at 55 percent due to favorable CDMO mix and process optimization measures. The fundamentals of our business remain healthy”.
Overall FY25 results, we have delivered revenues of Rs 5,554 crore , representing 10 percent growth and EBITDA stood at Rs 1,115 crore, growth of 40 percent. The EBITDA margin of 20.1 percent has substantially improved, supported by continuing operating leverage within CDMO business, he said..
Going ahead, we remain confident in our growth expectations as we look forward to executing on long lead programs, new assets ramp up with revenue increasing over FY25 with continued focus on operational excellence. Our capital allocation strategy remains unchanged, prioritizing investments into high value business opportunities, he added.
UNI KNR RN
Please log in to get detailed story.
Tags: #Laurus labs Q4FY25 net profit rises 208 pc to Rs 234 cr
More News
Air India Express launches Flash Sale with fares starting at Rs 1300

Air India Express launches Flash Sale with fares starting at Rs 1300

15 May 2025 | 12:41 PM

Kochi, May 15 (UNI) Air India Express announced a 'Flash Sale,' with Xpress Lite fares starting from Rs 1300 and ‘Zero Convenience Fee’ on the airline's website www.airindiaexpress.com and mobile app.

see more..
Rupee down 29 paise against USD

Rupee down 29 paise against USD

15 May 2025 | 10:04 AM

Mumbai, May 15 (UNI) The Rupee on Thursday tumbled down 29 paise at 85.55 in the opening session on brisk demand for US dollars by bankers and importers at the Forex market.

see more..
Sensex opens marginally up by 23 pts

Sensex opens marginally up by 23 pts

15 May 2025 | 10:03 AM

Mumbai, May 15 (UNI) Though the BSE Sensex on Thursday opened at 81,354.43, rising by 23 pts, it immediately went in the red as selling pressure was seen in FMCG, IT and Bankex stocks amid negative global cues.

see more..

Rupee opens at 85 55, down 29 paise against USD

15 May 2025 | 9:43 AM

UNI NV ARN.

see more..

Sensex opens at 81,354 43 up 23 pts and Nifty at 24,694 45 rising 28 pts

15 May 2025 | 9:21 AM

UNI NV ARN.

see more..